CN1660100A - Medication for treating diabetes and complication - Google Patents
Medication for treating diabetes and complication Download PDFInfo
- Publication number
- CN1660100A CN1660100A CN 02150937 CN02150937A CN1660100A CN 1660100 A CN1660100 A CN 1660100A CN 02150937 CN02150937 CN 02150937 CN 02150937 A CN02150937 A CN 02150937A CN 1660100 A CN1660100 A CN 1660100A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- medicine
- complication
- treatment
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicine for treating diabetes and its complications is prepared from ligustrazine and aminoguanidine.
Description
Technical field:
The present invention relates to field of medicaments, particularly diabetes are according to being a kind of medicine for the treatment of diabetes and complication thereof specifically.
Background technology:
Diabetes are serious healthy killers that the present mankind run into, and the symptom of diabetes comprises that hyperglycemia, Kohlenhydrate metabolism are complete, glycosuria and insulin sensitivity reduce, if these symptoms can not get treatment, then often causes severe complications.In the prior art, the Western medicine commonly used that is used to control type ii diabetes is divided into two classes: biguanides and sulfonylurea, biguanides can prevent over-drastic liver glyconeogenesis, sulfonylurea is mainly by stimulating insulin secretion, by improving insulin action and synthesize to come blood sugar lowering by suppressing liver sugar in some target tissue, the basic ideas of traditional TCM treatment of diabetes are YIN nourishing, QI invigorating, promote the production of body fluid, relieve inflammation or internal heat.The application of activating blood circulation to dissipate blood stasis class medicine in treating diabetes in recent years more and more comes into one's own.Aminoguanidine is the medicine commonly used of treatment diabetes, but because toxic and side effects is bigger, and make people to use.
Summary of the invention:
Technical problem to be solved by this invention is: because diabetes are serious healthy killers that the present mankind run into, the symptom of diabetes comprises that hyperglycemia, Kohlenhydrate metabolism are complete, glycosuria and insulin sensitivity reduce, if these symptoms can not get treatment, then often cause severe complications.In the prior art, the Western medicine commonly used that is used to control type ii diabetes is divided into two classes: biguanides and sulfonylurea, biguanides can prevent over-drastic liver glyconeogenesis, sulfonylurea is mainly by stimulating insulin secretion, by improving insulin action and synthesize to come blood sugar lowering by suppressing liver sugar in some target tissue, the basic ideas of traditional TCM treatment of diabetes are YIN nourishing, QI invigorating, promote the production of body fluid, relieve inflammation or internal heat.The application of activating blood circulation to dissipate blood stasis class medicine in treating diabetes in recent years more and more comes into one's own.Aminoguanidine is the medicine commonly used of treatment diabetes, but because toxic and side effects is bigger, and make people to use.The present invention is for solving the above-mentioned technical problem in the prior art, the technical scheme that is adopted provides a kind of medicine for the treatment of diabetes and complication thereof, described medicine is formed by ligustrazine and aminoguanidine, in a preferred embodiment of the invention, described medicine can make tablet, aqueous or oil-based suspension, can disperse powder or granule, emulsion, hard or soft capsule, syrup.Described preparation method thing can be according to the known any method preparation in preparation Pharmaceutical composition field, and described medicine can add excipient, granulating agent, disintegrating agent and lubricant.Dosage form of the present invention adopts the dosage form of approving on any pharmaceutics, comprises tablet, injection.
Experiment showed, that the ligustrazine with function of promoting blood circulation to disperse blood clots can increase the synthetic of vascular endothelial cell structure type nitricoxide synthase (cNOS), has the effect that reduces diabetic complication.
Aminoguanidine is a kind of inhibitor of special inducible nitric oxide synthase (iNOS), plays an important role in the relation of NO metabolism and disease.
The present invention and prior art contrast, and ligustrazine promotes the islet function recovery and alleviates the important official of the alliance infringement that diabetes cause to adjust the organ blood circulation by promoting the expression of cNOS.Amino takes off by anti-glycosylation and suppresses iNOS with to damage of diabetes islets of langerhans and insulin resistant, and limits amino flesh in low dose of range of application, alleviates its side effect, two kinds of medicines use together, can offset mutual weak point, learn from other's strong points to offset one's weaknesses, the effect of action compensating.
The specific embodiment:
A kind of medicine for the treatment of diabetes and complication thereof of the present invention, described medicine is formed by ligustrazine and aminoguanidine, wherein, in the 1kg medicine, described ligustrazine is 100g, and described aminoguanidine is 20g, surplus is the carrier in the prior art, comprise excipient, granulating agent, disintegrating agent and lubricant, in a preferred embodiment of the invention, described medicine can make tablet, aqueous or oil-based suspension, can disperse powder or granule, emulsion, hard or soft capsule, syrup.
Claims (2)
1, a kind of medicine for the treatment of diabetes and complication thereof is characterized in that: described medicine is formed by ligustrazine and aminoguanidine.
2, a kind of medicine for the treatment of diabetes and complication thereof of the present invention as claimed in claim, it is characterized in that: described dosage form adopts the dosage form of approving on any pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02150937 CN1660100A (en) | 2002-12-09 | 2002-12-09 | Medication for treating diabetes and complication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02150937 CN1660100A (en) | 2002-12-09 | 2002-12-09 | Medication for treating diabetes and complication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1660100A true CN1660100A (en) | 2005-08-31 |
Family
ID=35009843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02150937 Pending CN1660100A (en) | 2002-12-09 | 2002-12-09 | Medication for treating diabetes and complication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1660100A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507451B1 (en) | 2011-03-07 | 2013-08-13 | Zhili Wang | Method for the treatment of type II diabetes |
| CN104689300A (en) * | 2006-05-22 | 2015-06-10 | 加利福尼亚大学董事会 | Compositions and methods for the delivery of nitric oxide |
-
2002
- 2002-12-09 CN CN 02150937 patent/CN1660100A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689300A (en) * | 2006-05-22 | 2015-06-10 | 加利福尼亚大学董事会 | Compositions and methods for the delivery of nitric oxide |
| CN104689300B (en) * | 2006-05-22 | 2018-06-05 | 加利福尼亚大学董事会 | For the composition and method of oxygen conveying |
| US8507451B1 (en) | 2011-03-07 | 2013-08-13 | Zhili Wang | Method for the treatment of type II diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101053410A (en) | Health care product with weight-reducing function and its preparing method | |
| CN109820905A (en) | A kind of pharmaceutical composition and its application for treating insomnia | |
| CN1660100A (en) | Medication for treating diabetes and complication | |
| CN111743924A (en) | Marine plant extract for treating diabetes, composition and application | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN104001003A (en) | Oral liquid and sublingual spraying agent for treating diabetes | |
| CN110507707A (en) | A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN108114268A (en) | A kind of Chinese medicine composition for reducing blood glucose, preparation and preparation method and application | |
| CN109078089A (en) | A kind of anti-aging, the Chinese medicine composition and its preparation for preventing and treating osteoporosis | |
| CN1301738C (en) | Chinses medicine oral preparation for treating diabete and preparing method thereof | |
| CN101653551A (en) | Uric acid clearing medicament | |
| CN1192771C (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN1158080C (en) | Application of ligustrazine and aminoguanidin in treating II-type diabetes and its complication | |
| CN106038926A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN1234360C (en) | Complementary gain pain-killing medicine | |
| CN1053818C (en) | Ulcer powder | |
| CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
| CN1526430A (en) | Fracture setting medicine powder and its prepn process | |
| Singh et al. | View Point: Chronomedicine. A Boon for Emerging Diseases | |
| CN1507871A (en) | Use of phytanic acid for treating diabetes | |
| CN113082199A (en) | Pharmaceutical composition for treating nephropathy and preparation method thereof | |
| JP2022107117A (en) | Health food including paris polyphylla extract, and food or agent for improving sleep disorder | |
| CN116803406A (en) | Compound plant extract formula for reducing uric acid and pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |